Best marker to assess prognosis after Surgery for colon carcinoma: March 2005
First, I'll recall that in colorectal cancer, prognosis and recurrence risk are often assessed using certain biomarkers. The key ones I remember are CEA (carcinoembryonic antigen), CA 19-9, and maybe others like Ki-67 or p53. But for colon cancer specifically, CEA is the most commonly associated.
The question is from March 2005, so I need to consider if there were any new markers introduced around that time. I think CEA has been a standard for a long time. Let me confirm: CEA is a tumor marker used in monitoring response to treatment and detecting recurrence in colon cancer patients. It's not used for initial diagnosis but for follow-up. So after surgery, if CEA levels are high, it might indicate residual disease or higher risk of recurrence.
Now, the other options could be distractors. Let's say the options are A. CEA, B. CA 19-9, C. AFP, D. PSA. CA 19-9 is more for pancreatic cancer. AFP is for liver cancer, and PSA for prostate. So CEA would be the correct answer here.
Why is CEA the best marker? Because it's elevated in colon cancer and its levels correlate with tumor burden. Post-surgery, if levels don't decrease, it's a bad sign. Also, in follow-up, rising CEA can indicate recurrence.
Why are the others wrong? CA 19-9 is not specific for colon cancer. AFP and PSA are for other cancers. So the clinical pearl here is that CEA is the gold standard for monitoring colon cancer prognosis and recurrence after surgery. The student should remember that CEA is not for screening but for monitoring after diagnosis and treatment.
Putting it all together, the correct answer is CEA. I need to structure the explanation with the required sections, making sure each part is concise and within the character limit. Also, use bold for section names and key terms. Check the formatting rules again to avoid markdown errors. Let me draft that now.
**Core Concept**
The question tests knowledge of tumor markers in colorectal cancer prognosis. **CEA (carcinoembryonic antigen)** is the gold standard for monitoring response to therapy and predicting recurrence after surgical resection of colon carcinoma.
**Why the Correct Answer is Right**
**CEA** is a glycoprotein overexpressed in 60-70% of colorectal cancers. Post-surgery, persistently elevated CEA levels correlate with residual disease, while decreasing levels confirm complete resection. Serial CEA measurements help detect early recurrence, guiding adjuvant chemotherapy decisions. Its prognostic value stems from its tumor-specificity and dynamic correlation with tumor burden.
**Why Each Wrong Option is Incorrect**
**Option A:** **CA 19-9** is a marker for pancreatic and biliary tract cancers, not colon cancer.
**Option B:** **AFP (alpha-fetoprotein)** is specific to hepatocellular carcinoma and germ cell tumors.
**Option D:** **